Anchor Capital Advisors LLC Has $23.37 Million Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Anchor Capital Advisors LLC trimmed its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 14.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 85,570 shares of the medical research company’s stock after selling 14,461 shares during the period. Anchor Capital Advisors LLC owned approximately 0.30% of Bio-Rad Laboratories worth $23,370,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of BIO. Victory Capital Management Inc. boosted its position in shares of Bio-Rad Laboratories by 48.7% during the 4th quarter. Victory Capital Management Inc. now owns 17,671 shares of the medical research company’s stock worth $5,706,000 after acquiring an additional 5,790 shares in the last quarter. Artisan Partners Limited Partnership increased its stake in shares of Bio-Rad Laboratories by 38.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 151,691 shares of the medical research company’s stock valued at $48,980,000 after purchasing an additional 41,937 shares during the last quarter. Swedbank AB acquired a new position in shares of Bio-Rad Laboratories during the 1st quarter worth $1,824,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth $2,609,000. Finally, DAVENPORT & Co LLC acquired a new stake in Bio-Rad Laboratories in the first quarter valued at about $15,340,000. 65.24% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares of the company’s stock, valued at approximately $48,582.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Michael Crowley sold 369 shares of Bio-Rad Laboratories stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $281.91, for a total value of $104,024.79. Following the completion of the transaction, the executive vice president now directly owns 6,573 shares of the company’s stock, valued at approximately $1,852,994.43. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP James Barry sold 623 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the sale, the executive vice president now owns 147 shares in the company, valued at approximately $48,582.03. The disclosure for this sale can be found here. 17.06% of the stock is owned by insiders.

Bio-Rad Laboratories Trading Down 1.1 %

Shares of NYSE BIO opened at $329.75 on Friday. The firm has a 50 day moving average price of $313.46 and a two-hundred day moving average price of $307.98. The stock has a market cap of $9.41 billion, a P/E ratio of -31.83 and a beta of 0.95. Bio-Rad Laboratories, Inc. has a 52-week low of $261.59 and a 52-week high of $384.37. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 6.28.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, August 1st. The medical research company reported $3.11 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.99. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. The company had revenue of $638.50 million for the quarter, compared to analysts’ expectations of $645.79 million. During the same quarter in the previous year, the firm posted $3.00 earnings per share. Bio-Rad Laboratories’s revenue for the quarter was down 6.3% on a year-over-year basis. As a group, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.31 EPS for the current year.

Wall Street Analysts Forecast Growth

BIO has been the subject of a number of research reports. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Citigroup increased their price objective on shares of Bio-Rad Laboratories from $300.00 to $350.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 target price on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $401.00 price target on shares of Bio-Rad Laboratories in a report on Friday, August 16th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $315.00 price objective (down previously from $440.00) on shares of Bio-Rad Laboratories in a report on Monday, June 3rd. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $358.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.